



(51) International Patent Classification:

C07D 403/04 (2006.01) *C07D 417/14* (2006.01)
C07D 403/14 (2006.01) *A61K 31/4178* (2006.01)
C07D 407/14 (2006.01) *A61P 35/00* (2006.01)
C07D 409/14 (2006.01)

(21) International Application Number:

PCT/EP2010/059029

(22) International Filing Date:

24 June 2010 (24.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1500/CHE/2009 26 June 2009 (26.06.2009) IN
 2181/DEL/2009 21 October 2009 (21.10.2009) IN

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOCK, Mark G.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **GAUL, Christoph** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **GUMMADI, Venkateshwar Rao** [IN/IN]; #382, 3rd Cross, 2nd Main, South Avenue Layout, Gottigere, Bannerghatta Road, Bangalore 560 083 (IN). **SENGUPTA, Saumitra** [IN/IN]; 6/7 Central Park, Kolkata 700 032 (IN).

(74) Agent: **STRANG, Andrea**; NOVARTIS PHARMA AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: 1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17



(57) Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R^{53} , R^{54} , p , q and n are as defined herein. The compounds of the present invention have been found to be useful as 17 α -hydroxylase/C_{17,20}-lyase inhibitors.